316 related articles for article (PubMed ID: 15851648)
1. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
[TBL] [Abstract][Full Text] [Related]
2. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
3. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
[TBL] [Abstract][Full Text] [Related]
4. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Toto RD
Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure control, drug therapy, and kidney disease.
Contreras G; Greene T; Agodoa LY; Cheek D; Junco G; Dowie D; Lash J; Lipkowitz M; Miller ER; Ojo A; Sika M; Wilkening B; Toto RD;
Hypertension; 2005 Jul; 46(1):44-50. PubMed ID: 15897360
[TBL] [Abstract][Full Text] [Related]
6. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
7. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
[TBL] [Abstract][Full Text] [Related]
8. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
[TBL] [Abstract][Full Text] [Related]
10. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
Douglas JG; Agodoa L
Kidney Int Suppl; 2003 Feb; (83):S74-6. PubMed ID: 12864879
[TBL] [Abstract][Full Text] [Related]
11. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
Gassman JJ; Greene T; Wright JT; Agodoa L; Bakris G; Beck GJ; Douglas J; Jamerson K; Lewis J; Kutner M; Randall OS; Wang SR
J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S154-65. PubMed ID: 12819322
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
Appel LJ; Wright JT; Greene T; Kusek JW; Lewis JB; Wang X; Lipkowitz MS; Norris KC; Bakris GL; Rahman M; Contreras G; Rostand SG; Kopple JD; Gabbai FB; Schulman GI; Gassman JJ; Charleston J; Agodoa LY;
Arch Intern Med; 2008 Apr; 168(8):832-9. PubMed ID: 18443258
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
[TBL] [Abstract][Full Text] [Related]
14. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
15. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
[TBL] [Abstract][Full Text] [Related]
16. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
Sica DA
J Clin Hypertens (Greenwich); 2003; 5(2):159-67. PubMed ID: 12671332
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
Ruggenenti P; Perna A; Remuzzi G
J Am Soc Nephrol; 2001 Dec; 12(12):2832-2837. PubMed ID: 11729254
[TBL] [Abstract][Full Text] [Related]
18. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
Ruggenenti P; Perna A; Benini R; Remuzzi G
J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
[TBL] [Abstract][Full Text] [Related]
19. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
20. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
